Fasting and post-oral-glucose-load levels of methylglyoxal are associated with microvascular, but not macrovascular, disease in individuals with and without (pre)diabetes: The Maastricht Study
Autor: | Miranda T. Schram, Carroll A.B. Webers, M.M.J. van Greevenbroek, Casper G. Schalkwijk, Alphons J.H.M. Houben, Ronald M.A. Henry, C.J.H. van der Kallen, Coen D.A. Stehouwer, Nicolaas C. Schaper, Tos T. J. M. Berendschot, Koen D. Reesink, M. P. H. van de Waarenburg, Jean L.J.M. Scheijen, Nordin M J Hanssen |
---|---|
Přispěvatelé: | Medical Image Analysis, Vascular Medicine, ACS - Diabetes & metabolism, ACS - Atherosclerosis & ischemic syndromes, AGEM - Amsterdam Gastroenterology Endocrinology Metabolism, Dermatology, Interne Geneeskunde, RS: Carim - V01 Vascular complications of diabetes and metabolic syndrome, MUMC+: MA Med Staf Artsass Interne Geneeskunde (9), MUMC+: MA Alg Onderzoek Interne Geneeskunde (9), RS: NUTRIM - R1 - Obesity, diabetes and cardiovascular health, RS: MHeNs - R3 - Neuroscience, Oogheelkunde, MUMC+: MA UECM Oogartsen MUMC (9), MUMC+: University Eye Center Maastricht (3), MUMC+: *MA Oogheelkunde (3), RS: Carim - H07 Cardiovascular System Dynamics, Biomedische Technologie, RS: Carim - V02 Hypertension and target organ damage, RS: CAPHRI - R2 - Creating Value-Based Health Care, MUMC+: MA Endocrinologie (9), MUMC+: HVC Pieken Maastricht Studie (9), MUMC+: Centrum voor Chronische Zieken (3), MUMC+: MA Interne Geneeskunde (3) |
Rok vydání: | 2021 |
Předmět: |
Male
endocrine system diseases Endocrinology Diabetes and Metabolism 030204 cardiovascular system & hematology SDG 3 – Goede gezondheid en welzijn Gastroenterology 0302 clinical medicine Endocrinology Chronic kidney disease Prediabetes ALL-CAUSE MORTALITY Macrovascular disease Diabetes DICARBONYL STRESS Fasting General Medicine Middle Aged Pyruvaldehyde Cardiovascular disease Cardiovascular Diseases Female medicine.symptom medicine.medical_specialty END-PRODUCTS Renal function 030209 endocrinology & metabolism Prediabetic State 03 medical and health sciences INFLAMMATION SDG 3 - Good Health and Well-being Internal medicine Diabetes mellitus Methylglyoxal Internal Medicine medicine Humans PLASMA-LEVELS TYPE-1 Aged INCIDENT CARDIOVASCULAR-DISEASE ADVANCED GLYCATION ENDPRODUCTS business.industry nutritional and metabolic diseases Type 2 Diabetes Mellitus Glucose Tolerance Test medicine.disease Blood pressure ENDOTHELIAL DYSFUNCTION Albuminuria FOLLOW-UP business Kidney disease |
Zdroj: | Diabetes & Metabolism, 47(1):101148. Elsevier Masson s.r.l. Diabetes & metabolism, 47(1):101148. Elsevier Masson Diabetes & Metabolism, 47(1):101148. Elsevier Masson |
ISSN: | 1262-3636 |
Popis: | Aims: Reactive dicarbonyl compounds, such as methylglyoxal (MGO), rise during an oral glucose tolerance test (OGTT), particularly in (pre)diabetes. Fasting MGO levels are associated with chronic kidney disease (CKD) and cardiovascular disease (CVD) in patients with poorly controlled type 2 diabetes mellitus (T2DM). Yet, whether fasting or post-OGTT plasma MGO levels are associated with vascular disease in people with (pre)diabetes is unknown. Methods: Subjects with normal glucose metabolism (n = 1796; age: 57.9 ± 8.2 years; 43.3% men), prediabetes (n = 478; age: 61.6 ± 7.6 years; 54.0% men) and T2DM (n = 669; age: 63.0 ± 7.5 years; 67.0% men) from the Maastricht Study underwent OGTTs. Plasma MGO levels were measured at baseline and 2 h after OGTT by mass spectrometry. Prior CVD was established via questionnaire. CKD was reflected by estimated glomerular filtration rate (eGFR) and albuminuria; retinopathy was assessed using retinal photographs. Data were analyzed using logistic regression adjusted for gender, age, smoking, systolic blood pressure, total-to-HDL cholesterol ratio, triglycerides, HbA 1c, BMI and medication use. Odd ratios (ORs) were expressed per standard deviation of LN-transformed MGO. Results: Fasting and post-OGTT MGO levels were associated with higher ORs for albuminuria ≥ 30 mg/24 h [fasting: 1.12 (95% CI: 0.97–1.29); post-OGTT: 1.19 (1.01–1.41)], eGFR < 60 mL/min/1.73 m 2 [fasting: 1.58 (95% CI: 1.38–1.82), post-OGTT: 1.57 (1.34–1.83)] and retinopathy [fasting: 1.59 (95% CI: 1.01–2.53), post-OGTT: 1.38 (0.77–2.48)]. No associations with prior CVD were found. Conclusion: Fasting and post-OGTT MGO levels were associated with microvascular disease, but not prior CVD. Thus, therapeutic strategies directed at lowering MGO levels may prevent microvascular disease. |
Databáze: | OpenAIRE |
Externí odkaz: |